Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: 1. Voluntarily sign a written informed consent form; 2. Aged ≥ 18 years and ≤ 75 years , both males and females are eligible; 3. ECOG PS score of 0 or 1; 4. Patients with non-small cell lung cancer confirmed by histopathology or cytology, and with resectable clinical stage II-IIIB (T3N2) (according to the 8th edition of lung cancer TNM staging by the Union for International Cancer Control and the American Joint Committee on Cancer); 5. No prior anti-tumor treatment has been received; 6. No known EGFR sensitive mutations/ALK gene translocations; Exclusion Criteria: 1. Patients with large cell carcinoma, mixed-cell lung cancer, or those with small cell lung cancer components in the mixture; 2. Presence of locally advanced unresectable or metastatic disease; 3. Palliative local treatment for non-target lesions within 2 weeks before the first administration; receipt of non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, tumor necrosis fa…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source